Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice

Open access
Trenkwalder, Claudia, Hening, Wayne A., Montagna, Pasquale, Oertel, Wolfgang H., Allen, Richard P., Walters, Arthur S., Costa, Joao, Stiasny‐Kolster, Karin, Sampaio, Cristina · 2008 · Movement Disorders

Abstract

Only in the last three decades, the restless legs syndrome (RLS) has been examined in randomized controlled trials. The Movement Disorder Society (MDS) commissioned a task force to perform an evidence‐based review of the medical literature on treatment modalities used to manage patients with RLS. The task force performed a search of the published literature using electronic databases. The therapeutic efficacy of each drug was classified as being either efficacious, likely efficacious, investigational, nonefficacious, or lacking sufficient evidence to classify. Implications for clinical practice were generated based on the levels of evidence and particular features of each modality, such as adverse events. All studies were classed according to three levels of evidence. All Level‐I trials were included in the efficacy tables; if no Level‐I trials were available then Level‐II trials were included or, in the absence of Level‐II trials, Level‐III studies or case series were included. Only studies published in print or online before December 31, 2006 were included. All studies published after 1996, which attempted to assess RLS augmentation, were reviewed in a separate section. The following drugs are considered efficacious for the treatment of RLS: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Drugs considered likely efficacious are rotigotine, bromocriptine, oxycodone, carbamazepine, valproic acid, and clonidine. Drugs that are considered investigational are dihydroergocriptine, lisuride, methadone, tramadol, clonazepam, zolpidem, amantadine, and topiramate. Magnesium, folic acid, and exercise are also considered to be investigational. Sumanirole is nonefficacious. Intravenous iron dextran is likely efficacious for the treatment of RLS secondary to end‐stage renal disease and investigational in RLS subjects with normal renal function. The efficacy of oral iron is considered investigational; however, its efficacy appears to depend on the iron status of subjects. Cabergoline and pergolide (and possibly lisuride) require special monitoring due to fibrotic complications including cardiac valvulopathy. Special monitoring is required for several other medications based on clinical concerns: opioids (including, but not limited to, oxycodone, methadone and tramadol), due to possible addiction and respiratory depression, and some anticonvulsants (particularly, carbamazepine and valproic acid), due to systemic toxicities. © 2008 Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.22254

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 93 references

Cited by

See all 264

Metadata

Authors
Trenkwalder, C., Hening, W. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., Costa, J., Stiasny‐Kolster, K., & Sampaio, C.
Venue
Movement Disorders
Publisher
Wiley
Published
2008-10-16
Volume
23
Issue
16
Pages
2267-2302
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W2085792179
Cited by
264
References
93
FWCI
22.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice. https://app.cochat.ai/papers/10.1002/mds.22254
The paper
Trenkwalder, C., Hening, W. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., Costa, J., Stiasny‐Kolster, K., & Sampaio, C. (2008). Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice. Movement Disorders. https://doi.org/10.1002/mds.22254

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.